Drug Information
Drug General Information | |||||
---|---|---|---|---|---|
Drug ID |
D0Q5HW
|
||||
Former ID |
DNC007154
|
||||
Drug Name |
N6-methoxy-2-[(4-methylphenyl)ethynyl]adenosine
|
||||
Drug Type |
Small molecular drug
|
||||
Indication | Discovery agent | Investigative | [1] | ||
Structure |
![]() |
Download2D MOL |
|||
Formula |
C20H21N5O5
|
||||
Canonical SMILES |
CC1=CC=C(C=C1)C#CC2=NC3=C(C(=N2)NOC)N=CN3C4C(C(C(O4)CO)<br />O)O
|
||||
InChI |
1S/C20H21N5O5/c1-11-3-5-12(6-4-11)7-8-14-22-18(24-29-2)15-19(23-14)25(10-21-15)20-17(28)16(27)13(9-26)30-20/h3-6,10,13,16-17,20,26-28H,9H2,1-2H3,(H,22,23,24)/t13-,16-,17-,20-/m1/s1
|
||||
InChIKey |
QEUCNKIJAMGFSL-AEVYOOLXSA-N
|
||||
PubChem Compound ID | |||||
Target and Pathway | |||||
Target(s) | Adenosine A1 receptor | Target Info | Inhibitor | [1] | |
Adenosine A3 receptor | Target Info | Inhibitor | [1] | ||
KEGG Pathway | cGMP-PKG signaling pathway | ||||
cAMP signaling pathway | |||||
Sphingolipid signaling pathway | |||||
Neuroactive ligand-receptor interaction | |||||
Morphine addiction | |||||
NetPath Pathway | TCR Signaling Pathway | ||||
RANKL Signaling Pathway | |||||
PANTHER Pathway | Heterotrimeric G-protein signaling pathway-Gi alpha and Gs alpha mediated pathway | ||||
Heterotrimeric G-protein signaling pathway-Gq alpha and Go alpha mediated pathway | |||||
Reactome | Adenosine P1 receptors | ||||
G alpha (i) signalling eventsR-HSA-417973:Adenosine P1 receptors | |||||
G alpha (i) signalling events | |||||
WikiPathways | Nucleotide GPCRs | ||||
GPCRs, Class A Rhodopsin-like | |||||
GPCR ligand binding | |||||
GPCR downstream signalingWP80:Nucleotide GPCRs | |||||
GPCRs, Other | |||||
References | |||||
REF 1 | J Med Chem. 2007 Mar 22;50(6):1222-30. Epub 2007 Feb 20.N6-methoxy-2-alkynyladenosine derivatives as highly potent and selective ligands at the human A3 adenosine receptor. | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.